Adding a higher radiation dose to prostate tumors during standard radiotherapy
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether giving an extra, focused dose of radiation to the visible tumor inside the prostate can improve results for men with intermediate or high-risk prostate cancer that has not spread. The total treatment is given in 12 or 20 sessions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have prostate cancer confirmed by biopsy that has not spread to distant parts of the body
- Your cancer must be intermediate or high-risk based on T-stage, Gleason score, or lymph node involvement
- You need a tumor visible on an MRI scan that can be safely given a higher radiation dose
- You must be age 18 or older and in good general health (able to care for yourself)
- You must be willing to attend follow-up appointments and give written consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests radiation therapy for men with very high-risk prostate cancer that hasn't spread. It aims to see if targeting the tumor with radiation can help control the cancer in this highest risk group.
This trial tests whether adding an extra, targeted dose of radiation to the main tumor during standard radiation therapy can better control prostate cancer. It is for patients with intermediate or high-risk prostate cancer that has not spread, and who are eligible for a shorter course of radiation (20 sessions).
This trial tests a shorter course of radiation therapy with an extra 'boost' to the most aggressive part of the tumor, combined with hormone therapy, for men with high-risk or locally advanced prostate cancer that has not spread outside the pelvis.
This trial studies whether giving a moderate “boost” dose of radiation to the prostate—along with radiation to the pelvic area—can better control high-risk localized prostate cancer. You may benefit if you have high-risk disease and can safely receive radiation.
This trial tests a more concentrated radiation schedule for early-stage prostate cancer, using an extra high-dose “boost” delivered from inside the body. It may help by treating the prostate more precisely while aiming to keep side effects manageable.
This trial tests a newer, more precise radiation treatment that gives a higher dose to the main tumor while keeping radiation to the rest of the prostate the same. It is for men with intermediate- or high-risk prostate cancer who haven't had prior prostate radiation or removal.
Hear when a new Locally Advanced Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.